

ANAL

USOR 20189: Incyte: INCMGA00012vs Placebo with Paclitaxel/Carboplatin for Metastatic SCC AnalNCT04472429

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

BILIARY

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

BLADDER

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

BONE METS

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

BRAIN CANCER

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

BREAST

USOR 17079: Agendia: FLEX STUDY-MammaPrint Blueprint-Data Trial: NCT03053193

USOR 14059: Pharmacyclics: IBRUTINIB and HERCEPTIN for HER2 amplified NCT03379428

USOR 20431: PRESERVE2: Gi Therapeutics: TRILACICLIB vs Placebo with GEM/CARBO TRIPLE NEG NCT04799249

USOR 20417: Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer NCT03742102

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

CARCINOID

USOR 20189: Incyte: INCMGA00012vs Placebo with Paclitaxel/Carboplatin for Squamous Cell Anal NCT04472429

CERVICAL

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

COLON

USOR 20318: Mirati: MRTX849 with Cetuximab vs Folfox/Folfiri for KRASG12C mutation NCT04793958

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

ENDOMETRIAL

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C NCT03785249

ESOPHAGEAL

**USOR 20171: *ORIENT-15*:Covance: Sintilimab vs Plac w
Cis/Paclitaxel or Cis/5FU for SCC NCT03748134**

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

ESSENTIAL THROMBOCYTHEMIA

**USOR 19171: CTI BioPharma: Pacritinib vs Phys Ch for Myelofib,
PV=Myelofib,PEMyelofib NCT03165734**

FALLOPIAN

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

GALL BLADDER

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

GASTRIC

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

HEAD AND NECK

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

KAPOSIS SARCOMA

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

KIDNEY

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

LEUKEMIA

**USOR 20282: CABL001AUS04: Novartis: Asciminib in Chronic
Phase +/- T315 mutation NCT04666259**

**USOR 18263: BeiGene: Zanubrutinib in Patients with CLL intolerant to
Acalabrutinib NCT03206918**

LIVER

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

LUNG

**USOR 19239: KEAPSAKE: Calithera: Telaglenastat vs Placebo with Pembro + Chemo
wKEAP1NRF2mut NCT04265534**

**USOR 20249: Janssen: Amivantamab vs Placebo with Carbo and Pemetrexed with EGFR
EXON20ins NCT04538664**

**USOR 20250: MARIPOSA: Janssen: Amivantamab+Lazertinib or Osimertinib vs
Lazertinib EGFR NCT04487080**

**USOR 20412: LIBRETTO-432: Lilly: Selpercatinib f/b Definitive
Locoregional tx for IB-III RET+NCT04819100**

USOR 20331: Verastem: VS-6766(RAF/MEK inhib) as SA or in Combo with Defactinib(FAK inhib) in

KRAS-MT **NCT04620330**

USOR 19018: SAPPHIRE:Mirati: Sitravatinib and Nivolumab vs Docetaxel prev tx
Platinum+CHEK Inhib **NCT03906071**

**USOR 18164: Blueprint Medicine: BLU-667 for RET
mutation** **NCT03037385**

**USOR 20270: MRTX849 in Combination with Pembrolizumab in
Patients with Advanced NSCLCA with KRAS G12C** **NCT04613596**

**USOR 20139: Neo ADAURA-Neoadjuvant Osimertinib as Monotherapy
or in Combination with Chemotherapy versus Standard of Care
Chemotherapy Alone for the Treatment of Patients with EGFR
Resectable NSCLCA** **NCT04351555**

LYMPHOMA-HODGKINS

**USOR 11282: Seattle Genetics: Brentuximab Vedotin for pt ineligible
for standard chemo** **NCT01716806**

**USOR 18013: Seattle Genetics: Brentuximab Vedotin in Classical
Hodgkin Lymphoma** **NCT03646123**

LYMPHOMA- NON HODGKINS

USOR 11282: Seattle Genetics: Brentuximab Vedotin for pt ineligible for standard chemo
with PTCL **NCT01716806**

**USOR 18263: BeiGene:Zanubrutinib in Patients with SLL, WM
intolerant to Acalabrutinib** **NCT03206918**

MALIGNANT ADENOCARCINOMA

USOR 19151: Roche: MRTX849 For Solid Tumors with

KRASG12C

NCT03785249

MELANOMA-MERKEL CELL

**USOR 17144: Exicure: Cavrotolimod with Pembrolizumab or
Cemiplimab NCT03684785**

MYELODYSPLASTIC SYNDROME

**USOR 20438: STIMULUS-MDS-US: Novartis: Sabatolimab vs Plac with
Investigator Choice NCT03946670**

MYELOFIBROSIS

**USOR 19171: CTI Biopharma: Pacritinib Vs MD choice MF, PV-MF,
PET-MF NCT03165734**

**USOR 20177: TRANSFORM-1: Abbvie: Navitoclax with Ruxolitinib vs
Ruxolitinib alone NCT04472598**

**USOR 20346: XPORT-MF-035 SELINEXOR VERSUS TREATMENT OF
PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED
MYELOFIBROSIS NCT04562870**

OVARIAN

**USOR 20298: Verastem: VS-6766(RAF/MEK inhib) as SA or in Combo with
Defactinib(FAK inhib) NCT04625270**

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

PANCREATIC

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

PENILE

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

PERITONEAL

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

PROSTATE

**USOR 19144: Janssen: Biomarker (Blood test-Invitae) study to Determine DNA-Repair
Defects NCT03871816**

**USOR 16238: TRITON 3: Clovis: Ruaparib vs Physicians Choice for pt
with BRCA ½ or ATM NCT02975934**

**USOR 20248: Janssen: Niraparib vs Plac with Abiraterone Acetate+Predisone for patients with HRR or
Germline Mut NCT04497844**

**USOR 20138: CAPITELLO-281: AstraZeneca: Capivasertib+Abiraterone vs Plac+Abiraterone
for mHSPC w PTEN NCT04493853**

RECTAL

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

SARCOMA

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

SOLID TUMOR

USOR 17144: Exicure: Cavrotolimod with Pembrolizumab or Cemiplimab
NCT03684785

USOR 18164: Blueprint Medicine: BLU-667 for RET mutation
NCT03037385

USOR 19092: Janssen: *Erdafitinib for FGFR Gene Alterations*
NCT04083976

USOR 20186: *TAPISTRY*: Roche: Tumor agnostic Precision Immuno oncology and somatic targeting
NCT04589845

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C
NCT03785249

TESTICULAR

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C
NCT03785249

THYROID

USOR 18164: Blueprint Medicine: BLU-667 for RET mutation
NCT03037385

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C
NCT03785249

UROTHELIAL

USOR 19032: Janssen: Biomarker Study to Identify FGFR in Urothelial Cancer
NCT03955913

USOR 20172: *EVO-103*: Seattle Genetics: Enfortumab Vedotin in combo w anticancer Adv+Mets
NCT03288545

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

UTERINE

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

VAGINAL

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**

VULVAR

**USOR 19151: Roche: MRTX849 For Solid Tumors with
KRASG12C NCT03785249**